The 13th edition of the Maudsley Prescribing Guidelines is available NOW


For this 13th edition of the Maudsley Guidelines I am honoured to welcome Thomas Barnes and Allan Young as co-authors. Thomas and Allan are of course internationally renowned for their expertise in the treatment of psychosis and mood disorders, respectively. They take over from Carol Paton, who has edged perceptibly towards retirement, and Shitij Kapur, who has moved on to become the Dean of the faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne. My sincere and substantial gratitude is due to Carol and Shitij for their considerable contributions to several previous editions of The Guidelines. Carol in particular has written a great many sections (reflecting her very wide knowledge) has been an honest and candid critic of submissions from me and other contributors.

The Guidelines have grown somewhat organically since they were first produced as a 16 page pamphlet in 1994. For this edition we have reorganised sections into 14 chapters, each consisting of a more or less consistent theme of subject areas. Tables listing licenced uses and doses of antidepressants (a relic from the very first edition) have been removed – this information is readily available elsewhere – and new sections have been added. These include antipsychotics and thromboembolism, ECT augmentation of antipsychotics, psychotropics after bariatric surgery and restarting psychotropics after a period of non-compliance.

The Guidelines originated as a local document and gradually grew in size and scope into a reference used throughout the UK. More recent editions have been translated into several languages, including Japanese and Chinese, and The Guidelines have seen increased use in other English-speaking countries, particularly the USA. Because of this we have tried more than ever in this edition to make The Guidelines of worldwide relevance by including advice on the use of a range of psychotropics commonly prescribed in countries outside the UK.

The Authors:

David M. Taylor BSc, MSc, PhD, FFRPS, FRPharmS, is Director of Pharmacy and Pathology at the Maudsley Hospital and Professor of Psychopharmacology at King’s College, London.


Thomas R. E. Barnes, MBBS, MD, FRCPsych, DSc, is Emeritus Professor of Clinical Psychiatry at Imperial College London and joint-head of the Prescribing Observatory for Mental Health at the Royal College of Psychiatrists’ Centre for Quality Improvement.



Allan H. Young, MB, ChB, MPhil, PhD, FRCPC, FRCPsych, is Chair of Mood Disorders and is Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry at King’s College London, UK.